Hemosiderosis historical perspective

Hemosiderosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hemosiderosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hemosiderosis historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hemosiderosis historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hemosiderosis historical perspective
CDC on Hemosiderosis historical perspective
Hemosiderosis historical perspective in the news
Blogs on Hemosiderosis historical perspective
Directions to Hospitals Treating Hemosiderosis
Risk calculators and risk factors for Hemosiderosis historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

IPH was first described as "brown lung induration" by Rudolf Virchow in 1864 in patients after their death. Wilhelm Ceelen gave a more detailed description of the condition after autopsies revealed large amounts of hemosiderin in 2 children in 1931. In 1944, the antemortem diagnosis was made by Waldenstrom.

Historical Perspective

• IPH was first described as "brown lung induration" by Rudolf Virchow in 1864 in patients after their death.
• Wilhelm Ceelen gave a more detailed description of the condition after autopsies revealed large amounts of hemosiderin in 2 children in 1931.
• In 1944, the antemortem diagnosis was made by Waldenstrom